# LuCa-MERIT-1 (NCT05142189)

> Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05142189
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: BioNTech SE
- Conditions: Non-Small Cell Lung Cancer
- Interventions: BNT116; Cemiplimab; Docetaxel; Carboplatin; Paclitaxel; BNT316; anti-B7-H3 antibody conjugated to topoisomerase I inhibitor; anti-HER3 antibody conjugated to topoisomerase I inhibitor; Bispecific antibody for PD-L1 and VEGF-A; Osimertinib; ALK-inhibitor or RET-inhibitor
- Enrollment: 320
- Primary outcome: Cohorts 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, EGFR and ALK/RET: Occurrence of Dose-Limiting Toxicities (DLTs) During the DLT Observation Period
- Primary outcome: Cohorts 1 to 11, EGFR and ALK/RET: Occurrence of Treatment-Emergent Adverse Events (TEAEs) Reported by Relationship, Seriousness, and Grade
- Primary outcome: Cohort 6 only: Occurrence of Post-Surgical Adverse Events (AEs) Related to BNT116 and Cemiplimab
- Primary outcome: Cohort 6 only: Occurrence of Treatment-Related Delays to Surgery More Than 9 weeks Post the Last Dose of Neo-Adjuvant Treatment

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=luca-merit-1-nct05142189